9-(2,3,4,6-Tetramethyl-phenyl)-3,7-dimethyl-nona-2,4,6,8-tetraensaeure | 54757-03-8

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: 9-(2,3,4,6-Tetramethyl-phenyl)-3,7-dimethyl-nona-2,4,6,8-tetraensaeure
• 英文别名: 9-(2,3,4,6-tetramethyl-phenyl)-3,7-dimethyl-nona-2,4,6,8-tetraen-1-oic acid；(2E,4E,6E,8E)-3,7-dimethyl-9-(2,3,4,6-tetramethylphenyl)nona-2,4,6,8-tetraenoic acid
• CAS: 54757-03-8
• 化学式: C₂₁H₂₆O₂
• 分子量: 310.436
• InChiKey: DKBBCTUPHDHVRX-AQFIFDHZSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.5
• 重原子数：
  23
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• PROCESS FOR PREPARATION OF ACITRECIN
  申请人：EMCURE PHARMACEUTICALS LIMITED

  公开号：US20170275229A1

  公开（公告）日：2017-09-28

  The present invention provides a process for preparation of (2E,4E,6E,8E)-9-(4-methoxy-2,3,6-trimethyl)phenyl-3,7-dimethyl-nona-2,4,6,8}tetraenoate, an acitretin intermediate of formula (VI) with trans isomer≧97%, comprising of reacting 3-formyl-crotonic acid butyl ester of formula (V), substantially free of impurities, with 5-(4-methoxy-2,3,6-trimethylphenyl)-3-methyl-penta-2,4-diene-1-triphenyl phosphonium bromide of formula (IV) and isolating resultant compound of formula (VI), treating the filtrate with iodine for isomerization of the undesired cis intermediate and finally obtaining acitretin (I), with desired trans isomer≧97%.

  本发明提供了一种制备(2E,4E,6E,8E)-9-(4-甲氧基-2,3,6-三甲基)苯基-3,7-二甲基-壬-2,4,6,8-四烯酸}酯化物的方法，该化合物是维甲酸类似物的中间体，其反式异构体≧97％。该方法包括将公式（V）的3-甲酰基巴豆酸丁酯与公式（IV）的5-（4-甲氧基-2,3,6-三甲基苯基）-3-甲基戊-2,4-二烯-1-三苯基膦溴反应，分离得到公式（VI）的化合物，用碘处理滤液以异构化不需要的顺式中间体，最终获得所需的反式异构体≧97％的维甲酸。
• METHODS AND SYSTEMS FOR TREATING CELL PROLIFERATION DISORDERS WITH PSORALEN DERIVATIVES
  申请人：Immunolight, LLC

  公开号：US20130129757A1

  公开（公告）日：2013-05-23

  Psoralen compounds of Formula (I): wherein (N + Aryl) is a member selected from the group consisting of nitrogen containing aromatic heterocycles of formulae (i)-(iii): wherein Z is a group of formula: wherein R is C 1 -C 30 hydrocarbyl, which may be linear, branched or cyclic and contains from 1 to 15 carbon-carbon double bonds, which may be conjugated or unconjugated with one another or may include an aryl ring, and may contain one or more substituents; R 1 is hydrogen, aryl, heteroaryl, alkyl, cycloalkyl, heterocyclyl, alkenyl, alkynyl, alkene-aryl, alkene-heteroaryl, alkene-heterocyclyl, alkene-cycloalkyl, fused cycloalkylaryl, fused cycloalkylheteroaryl, fused heterocyclylaryl, fused heterocyclyheteroaryl, alkylene-fused cycloalkylaryl, alkylene-fused cycloalkylheteroaryl, alkylene-fused heterocyclylaryl, alkylene-fused heterocyclyheteroaryl; n is an integer from 1 to 8 and X is a pharmaceutically acceptable counter ion; and their use in methods for the treatment of a cell proliferation disorder in a subject, pharmaceutical compositions containing the psoralen derivatives, a kit for performing the method, and a method for causing an autovaccine effect in a subject using the method.

  公式（I）中的柏萘酮化合物： 其中（N + 芳基）是从式（i）-（iii）的氮杂环芳香族化合物中选择的成员： 其中Z是式子的一组： 其中R是C1-C30烃基，可以是线性，支链或环状，并含有1至15个碳-碳双键，可以共轭或不共轭，也可以包括芳香族环，并且可以含有一个或多个取代基；R1是氢，芳基，杂环芳基，烷基，环烷基，杂环烷基，烯基，炔基，烯基芳基，烯基杂环芳基，烯基杂环烷基，烯基环烷基，融合的环烷基芳基，融合的环烷基杂环芳基，融合的杂环烷基芳基，融合的杂环烷基杂环芳基，烷基-融合的环烷基芳基，烷基-融合的环烷基杂环芳基，烷基-融合的杂环烷基芳基，烷基-融合的杂环烷基杂环芳基；n是1至8的整数，X是药学上可接受的对离子； 它们用于治疗受体内细胞增殖障碍的方法，包含柏萘酮衍生物的制药组合物，用于执行该方法的工具包，以及使用该方法引起受体内自身免疫效应的方法。
• POLYAMINE CONJUGATES WITH ACIDIC RETINOIDS AND PREPARATION THEREOF
  申请人：Papaioannou, Dionysios

  公开号：EP1569694B1

  公开（公告）日：2009-11-25
• Photostabilization of Retinoids with Alkoxycrylene Compounds
  申请人：Bonda Craig A.

  公开号：US20110142771A1

  公开（公告）日：2011-06-16

  The photostabilizing electronic excited state energy—particularly singlet state energy from retinoid compounds—has been found to be readily transferred to (accepted by) α-cyanodiphenylacrylate compounds having an alkoxy radical in the four (para) position (hereinafter “alkoxycrylenes”) on one of the phenyl rings having the formula (I): wherein one of R 1 and R 2 is a straight or branched chain C 1 -C 30 alkoxy radical, preferably C 1 -C 8 , more preferably methoxy, and the non-alkoxy radical R 1 or R 2 is hydrogen; and R 3 is a straight or branched chain C 1 -C 30 alkyl radical, preferably C 2 -C 20 . The alkoxycrylene compounds of formula (I) significantly increase the photostability of retinoid compounds in a composition by at least 3-fold and as much as 10-fold or greater. The ability of the alkoxycrylene compounds to stabilize the retinoid compound is concentration dependent, with the amount of retinoid photostabilization increasing with the concentration of the alkoxycrylene compound.
• PHOTOSTABILIZATION OF RETINOIDS WITH ALKOXYCRYLENE COMPOUNDS
  申请人：Bonda Craig A.

  公开号：US20120065232A1

  公开（公告）日：2012-03-15

  The photostabilizing electronic excited state energy—particularly singlet state energy from retinoid compounds—has been found to be readily transferred to (accepted by) α-cyanodiphenylacrylate compounds having an alkoxy radical in the four (para) position (hereinafter “alkoxycrylenes”) on one of the phenyl rings having the formula (I): wherein one of R 1 and R 2 is a straight or branched chain C 1 -C 30 alkoxy radical, preferably C 1 -C 8 , more preferably methoxy, and the non-alkoxy radical R 1 or R 2 is hydrogen; and R 3 is a straight or branched chain C 1 -C 30 alkyl radical, preferably C 2 -C 20 . The alkoxycrylene compounds of formula (I) significantly increase the photostability of retinoid compounds in a composition by at least 3-fold.